Tenaya Therapeutics(US:TNYA)2022-04-14 17:52Company Vision and Mission - The company's vision is to transform and extend the lives of people and families fighting heart disease[6] - The company's mission is to discover, develop, and deliver curative therapies that address the underlying causes of heart disease[6] Pipeline and Programs - The company expects to file INDs for TN-201 and TN-301 in the second half of 2022[13] - TN-201, an AAV-based gene therapy for genetic Hypertrophic Cardiomyopathy (gHCM), targets over 115,000 patients in the US[20, 40] - TN-301, a small molecule HDAC6i program, addresses Heart Failure with Preserved Ejection Fraction (HFpEF), affecting over 3 million patients in the US[20, 64] - TN-401, a PKP2 gene therapy program for genetic Arrhythmogenic RV Cardiomyopathy (gARVC), targets over 70,000 patients in the US[20, 93] Capabilities and Foundations - The company has established >40 human iPSC-derived cardiomyocyte (iPSC-CM) models mimicking human disease phenotypes[23] - The company screened >1 billion capsids from >30 libraries for capsid engineering[23] - The company's cash balance of $2513 million is sufficient to fund operations at least into the second half of 2023[125, 126]